OSE Immunotherapeutics
Clinical trials sponsored by OSE Immunotherapeutics, explained in plain language.
Biotech developing immunotherapies for cancer and autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New vaccine aims to outsmart Drug-Resistant lung cancer
Disease control Recruiting nowThis Phase 3 trial tests a cancer vaccine called OSE2101 against standard chemotherapy (docetaxel) in 363 people with advanced non-small cell lung cancer that has stopped responding to immunotherapy. The vaccine targets multiple proteins found on cancer cells to help the immune s…
Phase 3 • Sponsor: OSE Immunotherapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New immune drug OSE-279 takes on advanced tumors
Disease control Recruiting nowThis study tests a new drug called OSE-279 that helps the immune system fight cancer. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The trial has three parts: finding the right dose, checking safety, and measuring how well t…
Phase 1/2 • Sponsor: OSE Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC